Medicinal Cannabis Matters | Friday roundup 16th May 2025
Medicinal Cannabis Matters – Our weekly round-up of what has been happening in the world of medicinal cannabis this week with key insights from Denmark, and new Musculoskeletal Pain Research.
Welcome back to our Friday Roundup, where we share the latest developments from the world of medicinal cannabis, with a special focus on the results from new studies and ongoing reforms. This week, we feature a new study on medical cannabis use in chronic musculoskeletal pain patients, and we explore the exciting expansion of Denmark’s medical cannabis programme.
Denmark’s Medical Cannabis Programme
Denmark is making waves in the European medical cannabis scene, with its government recently extending its pilot programme to provide more patients with access to cannabis-based medicines. Initially launched in 2018, the programme was set to end in 2023 but it has been renewed, reflecting the Danish government’s commitment to improving access to effective treatments for conditions like chronic pain, multiple sclerosis, and cancer.
This extension not only broadens patient access but also supports research and development into cannabis-based treatments. Denmark’s approach is one of regulation and quality control, ensuring that patients can access safe, high-quality medical cannabis products. With this move, further reassurance is being provided to patients across the world around the health benefits that alternative plant based medicine can bring.
Cannabis and Chronic Musculoskeletal Pain: New Insights from Research
A recent study published in Cureus has explored the patterns, efficacy, and cognitive effects of medical cannabis use in patients with chronic musculoskeletal pain. The study, published in Cureus, provides new insights into how cannabis-based treatments can benefit those suffering from persistent pain.
The research highlights that medical cannabis can significantly reduce pain intensity, improve mobility, and also provide cognitive benefits for patients with conditions like osteoarthritis, rheumatoid arthritis, and fibromyalgia. The study suggests that medical cannabis, particularly THC and CBD-based therapies, may offer a safer and more effective alternative to traditional pain management methods, such as opioids.
One of the most important takeaways from the study is the potential for medicinal cannabis to improve not just physical symptoms but also cognitive function. Many chronic pain patients struggle with issues such as memory and concentration, but the research suggests that medical cannabis could help mitigate these impairments and improve overall quality of life for a patient.
The Bigger Picture for medicinal cannabis patients
The progress in Denmark, and the growing evidence supporting cannabis in chronic pain treatment are both positive shifts for the future of medicinal cannabis and are paving the way for a more regulated, patient-centric cannabis landscape.
If you’re a patient seeking alternative relief, then the best place to start is with our online eligibility checker to see if you can become a medicinal cannabis patient in Jersey, Guernsey or the Isle of Man.
Disclaimer:
This blog post and the following featured articles are for information only and any articles on external platforms may be amended at any time. Articles that we refer to in our weekly roundup do not reflect the views of Medicann.
